Jolanda Howe Sells 658 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock

Key Points

• Mirum Pharmaceuticals SVP Jolanda Howe sold 658 shares at an average price of $100, generating $65,800. The Rule 10b5-1 transaction reduced her direct ownership by 51.65% to 616 shares.
• Howe has also sold more than 47,000 shares in other transactions since June, including 40,000 shares for $4 million on August 18.
• MIRM recently traded near $100.63, while analysts maintain a “Moderate Buy” consensus with an average price target of $137.31. The company’s latest revenue rose 37.9% year over year to $176.24 million, although its quarterly loss exceeded expectations.

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) SVP Jolanda Howe sold 658 shares of the stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $100.00, for a total value of $65,800.00. Following the transaction, the senior vice president directly owned 616 shares of the company's stock, valued at approximately $61,600. This trade represents a 51.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jolanda Howe also recently made the following trade(s):

• On Tuesday, August 18th, Jolanda Howe sold 40,000 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $100.00, for a total value of $4,000,000.00.
• On Monday, August 3rd, Jolanda Howe sold 1,840 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $105.29, for a total value of $193,733.60.
• On Wednesday, July 1st, Jolanda Howe sold 2,721 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $120.00, for a total value of $326,520.00.
• On Wednesday, June 17th, Jolanda Howe sold 2,594 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $101.95, for a total value of $264,458.30.

Mirum Pharmaceuticals Stock Performance

MIRM traded up $0.80 during trading hours on Thursday, hitting $100.63. The stock had a trading volume of 453,033 shares, compared to its average volume of 857,573. The company's fifty day simple moving average is $109.55 and its 200 day simple moving average is $101.74. Mirum Pharmaceuticals, Inc. has a 1 year low of $63.23 and a 1 year high of $130.00. The stock has a market cap of $6.53 billion, a PE ratio of -6.92 and a beta of 0.49. The company has a quick ratio of 2.74, a current ratio of 2.86 and a debt-to-equity ratio of 1.28.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.32). The business had revenue of $176.24 million for the quarter, compared to analysts' expectations of $166.33 million. Mirum Pharmaceuticals had a negative net margin of 139.18% and a negative return on equity of 36.28%. Mirum Pharmaceuticals's revenue for the quarter was up 37.9% compared to the same quarter last year. During the same period last year, the company earned ($0.12) earnings per share. Equities analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.31 earnings per share for the current year.

Wall Street Analysts Forecast Growth

MIRM has been the subject of a number of recent research reports. Morgan Stanley set a $137.00 price objective on shares of Mirum Pharmaceuticals in a research note on Thursday, August 6th. Citizens Jmp reaffirmed a "market outperform" rating and issued a $137.00 price target on shares of Mirum Pharmaceuticals in a report on Thursday, August 27th. CLSA set a $146.00 price target on Mirum Pharmaceuticals in a research report on Monday, June 15th. Wall Street Zen upgraded Mirum Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday, August 29th. Finally, Raymond James Financial reissued a "strong-buy" rating and set a $165.00 price objective on shares of Mirum Pharmaceuticals in a report on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Mirum Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $137.31.

Institutional Trading of Mirum Pharmaceuticals

Large investors have recently modified their holdings of the business. Jupiter Topco LLC purchased a new stake in Mirum Pharmaceuticals in the second quarter valued at approximately $691,672,000. California State Teachers Retirement System grew its stake in Mirum Pharmaceuticals by 12,542.7% in the 2nd quarter. California State Teachers Retirement System now owns 5,622,989 shares of the company's stock worth $658,283,000 after buying an additional 5,578,513 shares in the last quarter. BlackRock Inc. bought a new position in shares of Mirum Pharmaceuticals in the 2nd quarter worth $513,945,000. William Blair Investment Management LLC bought a new position in shares of Mirum Pharmaceuticals in the 2nd quarter worth $164,453,000. Finally, Janus Henderson Group PLC raised its position in shares of Mirum Pharmaceuticals by 21.4% during the 4th quarter. Janus Henderson Group PLC now owns 6,065,308 shares of the company's stock valued at $479,050,000 after buying an additional 1,067,722 shares in the last quarter.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company's primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum's lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source